In The News
Clyde & Co sued by insurers over indemnity advice
‘Our integrations are on track’: Class action flags WiseTech response to short seller report
Russells partner accused of bullying told lawyer she was ‘very negative’
Cornwalls hits back at $4.8M negligence suit by former client
Top silk to join NSW Supreme Court
NAB accused of rescinding job offer to pregnant employee
Ex-Bulldogs player must produce messages between solicitor and doctor
AI pathology invention just administrative tool, not patentable: IP Australia
Ultimate Fighting Championship gym exec not on the hook for $5M judgment
Bird & Bird snags DLA Piper partner for Sydney office
Please login to bookmarkClose

A full bench of the Federal Court has dismissed an appeal by drug giant GlaxoSmithKline in a patent infringement case it brought over planned generic versions of its sustained-release Panadol.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au